Figure 1.

Comparisons between serum growth-related oncogene product β (GROβ) levels and clinicopathological parameters in colorectal cancer (CRC). (A) Enzyme-linked immunosorbent assay results show serum GROβ levels in patients with colorectal cancer (CRC), both preoperatively (CRC preo; n = 123) and postoperatively (CRC post: n = 66 samples), compared to healthy controls (HC: n = 88) and patients with non-tumor diseases (Non-T controls: n = 125). B-H. Serum GROβ levels were compared among samples with different (B) tumor-node-metastasis stages (I-IV), (C) depths of infiltration, (D) histological grades, (E) presence of tumor embolus, (F) presence of lymph node (LN) metastasis, (G) gross pathologic tumor types, and (H) patient gender. Boxes represent the distribution of data between the 25th and 75th percentiles (the internal horizontal line is the median, and the dots indicate outlying points).